uniQure N.V. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
uniQure announced FDA acceptance of BLA for ifezuntirgene inilparvovec (AMT-130) under Accelerated Approval pathway with Priority Review and PDUFA target date of May 1, 2027. The lead program showed 61% slowing of disease progression on Total Functional Capacity (primary endpoint for confirmatory study) at 48 months in 12 high-dose patients (nominal p=0.008). Company has $768.4M cash as of Sept 30, 2026 (vs. $622.5M Dec 31, 2025), expects runway into 2030; FDA-aligned confirmatory study (~200 patients, 2:1 randomization) expected to begin U.S. screening by end of 2026. Q3 2026 net loss was $61.2M ($0.88 per share) vs. $80.5M ($1.38 per share) in Q3 2025.
Why this rating
Priority Review and aligned confirmatory study design de-risk lead program; $768.4M cash (100% of market cap) funds multi-year runway. Material near-term catalyst (May 2027 decision) for ~$765M company. Regulatory approval would be transformational but not assured.
Price action (we called it positive)
before filing · preread $24.05 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.